Themis Medicare Limited (THEMISMED) AI Stock Analysis

• Market Cap: ₹9.43B
• Dividend Yield: 0.47%
• Average Volume (3M): 6.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: -18.86%
• EPS Growth: -150.92%
• Country: IN
• Employees: 1,509
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.39
• Shares Outstanding: 92,040,120
• 10 Day Avg. Volume: 6,301
• 30 Day Avg. Volume: 6,868
• PEG Ratio: -1.45
• Price to Book (P/B): 3.39
• Price to Sales (P/S): 3.37
• P/FCF Ratio: 70.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: ₹111.00 ▲(4.42% Upside)

Themis Medicare Limited's overall stock score is primarily influenced by its solid financial performance, which is a strong point for the company. However, the bearish technical indicators and negative P/E ratio significantly weigh down the score, indicating potential risks in the stock's current valuation and market momentum. The lack of earnings call data and notable corporate events means these factors did not influence the score.

Positive Factors

Revenue Model

Themis Medicare's diverse revenue model, including direct sales and strategic partnerships, supports sustainable growth and market expansion.

Cash Flow Management

Strong cash flow management enhances financial flexibility, enabling strategic investments and resilience against market fluctuations.

Gross Profit Margins

Maintaining high gross profit margins reflects operational efficiency, contributing to long-term profitability and competitive positioning.

Negative Factors

Revenue Growth Decline

Negative revenue growth suggests challenges in market demand or competitive pressures, potentially impacting future earnings and market share.

Net Profit Margin Volatility

Volatile net profit margins indicate potential inefficiencies or market pressures, which could affect long-term profitability and investor confidence.

Debt Increase

Rising debt levels may strain financial resources, limiting the company's ability to invest in growth opportunities and manage economic downturns.

Themis Medicare Limited Business Overview & Revenue Model

Company Description

Themis Medicare Limited (THEMISMED) is a healthcare company that specializes in the development, manufacturing, and distribution of pharmaceutical products and medical devices. Operating within the pharmaceutical and biotech sectors, THEMISMED focuses on innovative therapies and solutions aimed at improving patient outcomes across various medical conditions. The company’s core products include prescription medications, over-the-counter pharmaceutical products, and specialized medical devices designed to address unmet medical needs.

How the Company Makes Money

Themis Medicare Limited generates revenue primarily through the sale of its pharmaceutical products and medical devices. The company's revenue model is built on direct sales to healthcare providers, pharmacies, and hospitals, as well as through distribution agreements with third-party partners. Key revenue streams include prescription medications, which often have higher margins, and medical devices that cater to specific therapeutic areas. Additionally, THEMISMED may benefit from strategic partnerships with other pharmaceutical companies for co-development or co-marketing agreements, enhancing its market reach and product offerings. The company also explores opportunities in licensing agreements for its proprietary technologies and products, which can provide an additional source of income.

Themis Medicare Limited Financial Statement Overview

Summary

Themis Medicare Limited exhibits robust growth and operational efficiency as seen in its income statement, with strong revenue and gross profit metrics. The balance sheet shows a stable financial footing with managed leverage and solid equity. Cash flow statements indicate effective cash management, although there is room for improvement in aligning free cash flow with net income. Overall, the company is in a solid position with potential for further financial optimization.

Income Statement

Themis Medicare Limited demonstrates strong revenue growth with a consistent increase in total revenue over the years, highlighted by a significant jump from 2020 to 2025. The company has maintained high gross profit margins, indicating efficient cost management. However, net profit margin has been volatile, with a noticeable decline in the recent period, suggesting potential challenges in managing expenses or increased competition affecting profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a healthy equity ratio and improving return on equity. The debt-to-equity ratio is managed well, indicating balanced leverage, though there is a slight increase in total debt in recent periods. Overall, the company's financial structure supports its growth but could benefit from further equity strengthening.

Cash Flow

Cash flows show a positive trajectory with improving operating cash flows and a strong free cash flow recovery after negative figures in earlier years. However, the free cash flow to net income ratio highlights some inconsistencies, suggesting areas for improvement in cash generation relative to profits. The company has been able to manage capital expenditures effectively to enhance free cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.80B	4.06B	3.82B	3.54B	3.95B	2.31B
Gross Profit	2.10B	2.74B	2.42B	2.36B	2.43B	1.50B
EBITDA	108.31M	490.48M	733.17M	789.56M	1.02B	531.16M
Net Income	-90.71M	298.33M	435.24M	569.01M	728.81M	357.03M
Balance Sheet
Total Assets	0.00	5.88B	5.66B	5.14B	4.28B	3.71B
Cash, Cash Equivalents and Short-Term Investments	128.37M	65.59M	99.22M	125.47M	202.79M	190.18M
Total Debt	0.00	829.88M	957.92M	923.75M	797.32M	871.82M
Total Liabilities	-4.03B	1.85B	1.89B	1.75B	1.40B	1.53B
Stockholders Equity	4.03B	4.03B	3.78B	3.39B	2.87B	2.19B
Cash Flow
Free Cash Flow	0.00	192.84M	36.76M	-126.55M	137.67M	389.36M
Operating Cash Flow	0.00	347.10M	220.94M	160.93M	343.94M	569.75M
Investing Cash Flow	0.00	-121.74M	-159.48M	-239.62M	-155.86M	-156.51M
Financing Cash Flow	0.00	-258.98M	-87.70M	1.36M	-175.47M	-256.47M

Themis Medicare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 106.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THEMISMED, the sentiment is Negative. The current price of 106.3 is below the 20-day moving average (MA) of 115.57, below the 50-day MA of 124.00, and below the 200-day MA of 132.92, indicating a bearish trend. The MACD of -4.91 indicates Positive momentum. The RSI at 35.93 is Neutral, neither overbought nor oversold. The STOCH value of 20.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:THEMISMED.

Themis Medicare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLISSGVS	75 Outperform	₹17.63B	16.05	―	0.31%	7.51%	71.81%
JAGSNPHARM	67 Neutral	₹13.58B	21.83	―	1.23%	24.60%	153.56%
WANBURY	60 Neutral	₹8.77B	20.36	―	―	8.92%	-5.56%
THEMISMED	54 Neutral	₹9.43B	―	―	0.47%	-18.86%	-150.92%
KOPRAN	53 Neutral	₹6.46B	36.66	―	2.24%	-6.96%	-66.75%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Themis Medicare Limited Corporate Events

Themis Medicare Announces Special Window for Share Transfer Requests

Themis Medicare Limited has announced a newspaper publication regarding a special window for the re-lodgement of transfer requests for physical shares. This initiative is in line with the SEBI circular and aims to facilitate shareholders in managing their physical share transfers, potentially impacting the company’s shareholder relations and compliance with regulatory requirements.